Delivering siRNA and Chemotherapeutic Molecules Across BBB and BTB for Intracranial Glioblastoma Therapy

Yang, Zhenzhen; Gao, Wei; Liu, Yujie; Pang, Natalie; Qi, Xian

doi:10.1021/acs.molpharmaceut.6b00819

Cited by 35 publications

(23 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is due to a couple of factors. The first and the most important is the presence of the blood brain barrier (BBB) which blocks the passage for over 90% of the agents used in the current clinical setting [16,17]. Secondly, GBMs have a propensity to quickly develop resistance to the therapeutic agents which penetrate the BBB, through multiple molecular pathways [18][19][20].…”

Section: Resultsmentioning

confidence: 99%

The Cytotoxic Effect of Rtks Inhibitors on Glioblastoma Cells. A Mathematical Model for Treatment Protocols Optimization

Brandusa¹,

Vatu²,

Purcaru³

et al. 2020

Rev. Chim.

View full text Add to dashboard Cite

Medical oncology has seen an exponential growth in the last 20 years with the vast majority of malignancies receiving new therapeutic options with substantial benefits to patients� survival and quality of life. Glioblastomas (GBMs), however, have remained largely incurable, with over 90% of patients dying within 5 years of diagnosis. The estimation of a dose�effect type ratio, regarding the action of an oncological drug on tumor cells, leads to relevant conclusions in establishing the optimal medication, specific to the chemotherapeutic act. The identification of the optimal dose of agent is very important, based on experiments on cell lines with regards to cellular kinetics. In this study, we developed a mathematical model based on the specific transfer function of a dose�response action type of a drug on tumor cells in vitro.

show abstract

Section: Resultsmentioning

confidence: 99%

The Cytotoxic Effect of Rtks Inhibitors on Glioblastoma Cells. A Mathematical Model for Treatment Protocols Optimization

Brandusa¹,

Vatu²,

Purcaru³

et al. 2020

Rev. Chim.

View full text Add to dashboard Cite

show abstract

“…Therefore, surface charge decides the fate of the nanocarriers. However, to target the brain, cationic nanocarriers are more useful, as they can easily pass through the BBB by adsorptive-mediated transcytosis (AMT; Yang et al 2017).…”

Section: Targeting Glioblastoma Multiforme: An Effective Approach Via Nanocarriersmentioning

confidence: 99%

Multifunctional lipidic nanocarriers for effective therapy of glioblastoma: recent advances in stimuli-responsive, receptor and subcellular targeted approaches

Hegde

Prabhu²,

Mutalik

et al. 2021

J. Pharm. Investig.

View full text Add to dashboard Cite

Background Glioblastoma, or glioblastoma multiforme (GBM), remains a fatal cancer type despite the remarkable progress in understanding the genesis and propagation of the tumor. Current treatment modalities, comprising mainly of surgery followed by adjuvant chemoradiation, are insufficient for improving patients' survival owing to existing hurdles, including the blood–brain barrier (BBB). In contemporary practice, the prospect of long-term survival or cure continues to be a challenge for patients suffering from GBM. This review provides an insight into the drug delivery strategies and the significant efforts made in lipid-based nanoplatform research to circumvent the challenges in optimal drug delivery in GBM. Area covered Owing to the unique properties of lipid-based nanoplatforms and advancements in clinical translation, this article describes the application of various stimuli-responsive lipid nanocarriers and tumor subcellular organelle-targeted therapy to give an idea about the strategies that can be applied to enhance site-specific drug delivery for GBM. Furthermore, active targeting of drugs via surface-modified lipid-based nanostructures and recent findings in alternative therapeutic platforms such as gene therapy, immunotherapy, and multimodal therapy have also been overviewed. Expert opinion Lipid-based nanoparticles stand out among the other nanocarriers explored for GBM drug delivery, as they support both passive and active drug targeting by crossing/bypassing the BBB at the same time minimizing toxicity and projects better pharmacological parameters. Although these nanocarriers could be a plausible choice for treating GBM, in-depth research is essential to advance neuro-oncology research and enhance outcomes in patients with brain tumors.

show abstract

“…By combining VEGF siRNA and docetaxel therapy, this liposome system induced VEGF silencing, inhibition of tumor growth, and prolonged survival time (Z. Z. Yang, Gao, Liu, Pang, & Qi, ).…”

Section: Recent Advances In Non‐viral Delivery Vectors For Sirna Delimentioning

confidence: 99%

Theranostic small interfering RNA nanoparticles in cancer precision nanomedicine

Chen

Krishnamachary

Pachecho‐Torres

et al. 2019

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Due to their ability to effectively downregulate the expression of target genes, small interfering RNA (siRNA) have emerged as promising candidates for precision medicine in cancer. Although some siRNA‐based treatments have advanced to clinical trials, challenges such as poor stability during circulation, and less than optimal pharmacokinetics and biodistribution of siRNA in vivo present barriers to the systemic delivery of siRNA. In recent years, theranostic nanomedicine integrating siRNA delivery has attracted significant attention for precision medicine. Theranostic nanomedicine takes advantage of the high capacity of nanoplatforms to ferry cargo with imaging and therapeutic capabilities. These theranostic nanoplatforms have the potential to play a major role in gene specific treatments. Here we have reviewed recent advances in the use of theranostic nanoplatforms to deliver siRNA, and discussed the opportunities as well as challenges associated with this exciting technology. This article is categorized under: Diagnostic Tools > In Vivo Nanodiagnostics and Imaging Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Implantable Materials and Surgical Technologies > Nanomaterials and Implants

show abstract

Delivering siRNA and Chemotherapeutic Molecules Across BBB and BTB for Intracranial Glioblastoma Therapy

Cited by 35 publications

References 38 publications

The Cytotoxic Effect of Rtks Inhibitors on Glioblastoma Cells. A Mathematical Model for Treatment Protocols Optimization

The Cytotoxic Effect of Rtks Inhibitors on Glioblastoma Cells. A Mathematical Model for Treatment Protocols Optimization

Multifunctional lipidic nanocarriers for effective therapy of glioblastoma: recent advances in stimuli-responsive, receptor and subcellular targeted approaches

Theranostic small interfering RNA nanoparticles in cancer precision nanomedicine

Contact Info

Product

Resources

About